Postdoctoral Fellow,2006 Molecular Oncology, Van Andel Institute, Grand Rapids, MI,
Ph.D., 2002 Fudan University Zhongshan Hospital, Shanghai, China.
M.D., 1995 Fudan University Shanghai Medical College, Shanghai, China.
2015- Present Assistant Professor, Department of Biomedical Sciences, East Tennessee
State University, Johnson City, TN
2013-2015 Research Assistant Professor, Van Andel Research Institute, Grand
2010-2013 Senior Research Scientist, Van Andel Research Institute, Grand
2006-2010 Research Scientist, Van Andel Research Institute, Grand Rapids,
The success of molecular targeted therapy in cancer depends on knowledge of essential
pathways that contribute to oncogenesis and the molecular targets that control pathway
activity. The major research interest of my lab is to understand the role of MET signaling
pathway in cancer, with primary focus on glioblastoma and hepatocellular carcinoma.
We use both in vitro cell based assays and in vivo animal models to understand the
molecular regulation of MET and Tyrosine Kinase signaling pathways in order to develop
therapeutic strategies for cancer treatment.
1) To determine the molecular mechanisms of MET-targeted therapy and the therapeutic
2) To identify the underlying causes and treatments for glioblastoma.
3) To develop preclinical animal modeling systems for studying tumor biology
and therapeutics in glioblastoma.
1. Yuanzheng He, Jingjing Shi, Wei Yi, Xin Ren, Xiang Gao, Jianshuang Li, Nanyan
Wu, Kevin Weaver, Qian Xie, Sok Kean Khoo, Tao Yang, Xiaozhu Huang, Karsten Melcher, and H. Eric Xu. Discovery
of a highly potent glucocorticoid for asthma treatment. Cell Discovery, (1):15035,
2. Jennifer Johnson, Maria Libra Ascierto, Liang Kang, Robert Bradley, Sandeep
Mittal, Michael Briggs, Kirk Tanner, Micheal E. Berens, Francesco M. Marincola,, George
F. Vande Woude, and Qian Xie. Identifying HGF signature for MET-targeted therapy in glioblastoma. Journal of Translational
Medicine, 17;13(1):306, 2015.
3. Qian Xie*, Sandeep Mittal, and Michael E. Berens. Targeting adaptive glioblastoma: an overview
of proliferation and invasion. Neuro-Oncology (16): 12, 1575-1584, 2014 [*Corresponding
4. Qian Xie*, Yanli Su, Karl Dykema, Jennifer Johnson, Julie Koeman, Valeria De Giorgi, Alan
Huang, Robert Schlegel, Curt Essenburg, Liang Kang, Keiichi Iwaya, Shuhji Seki, Sok
Kean Khoo, Boheng Zhang, Franco M. Buonaguro, Francesco M. Marincola, Kyle Furge,
George F. Vande Woude, and Nariyoshi Shinomiya*. Overexpression of HGF promotes HBV-Induced
hepatocellular carcinoma progression and is an effective biomarker for Met-targeting
therapy. Genes & Cancer, 4:247-60, 2013 [* Co- corresponding authors] Highlighted
as Cover Story of the July/August issue
5. Cui Y, Wu W, Zhou Y, Xie Q, Liu T, Jin J, Liu K. HSP27 expression levels are associated with the sensitivity
of hepatocellular carcinoma cells to 17-allylamino-17-demethoxy geldanamycin. Future
Oncology (3):411-8. 2013
6. Xie, Q., Vande Woude, GF., Berens, ME. RTK inhibition: looking for the right pathways toward
a miracle. Future Oncology (8):1397-1400, 2012 (Priority Review)
7. Qian Xie*, Robert Bradley, Julie Koeman, Andrea Worschech, Liang Kang, Yanli Su, Lisa Kefene,
Curt Essenburg, Dafna Kaufman, Tom DeKoning, Mark Enter, Timothy J. ORourke, Francesco
M. Marincola, George F. Vande Woude*. HGF-autocrine activation in glioblastoma predicts
the sensitivity to MET inhibition in glioblastoma. Proc Natl Acad Sci U S A. 10;109(2):570-5,
2012 [* Co-corresponding authors]
8. Xie Q, Wondergem R., Shen YH, Cavey G, Ke JY, Thompson R, Bradley R, Daughtery-Holtrop
J, Xu Y, Chen E, Omar H, Wenkert D, Xu, HE, and Vande Woude GF. 17AAG, through hydrophobic
binding, targets mitochondrial VDAC and inhibits cell invasion. Proc Natl Acad Sci
U S A. 108(10):4105-10, 2011